You can buy or sell CLRB and other stocks, options, ETFs, and crypto commission-free!
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. Read More The company was founded in June,1996 and is headquartered in Florham Park, NJ.
Florham Park, New Jersey
52 Week High
52 Week Low
Seeking AlphaMay 16
Cellectar down 25% on $10M capital raise
Cellectar Biosciences (CLRB -25.4% ) obliterates yesterday's 24% spike with its $10M direct stock offering to institutional investors.
Seeking AlphaMay 13
Cellectar's CLR 131 Fast Track'd for multiple myeloma; shares up 6%
Thinly traded nano cap Cellectar Biosciences (CLRB +5.6% ) is up on more than a 4x surge in volume on the heels of Fast Track status in the U.S. for lead candidate CLR 131 for the fourth line (or greater) treatment of relapsed/refractory multiple myeloma.
Yahoo FinanceMay 13
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
Designation could accelerate CLR 131 development and underscores the need for new treatments FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CLR 131 in fourth line or later relapse/refractory multiple myeloma. CLR 131 is the ...
Expected Aug 8, Pre-Market